Skip to content
OpenCapital
Get started

Royalty Pharma RPRX Cash & Equivalents

Cash & Equivalents at other companies

XOMA Corporation logo
XOMA CorporationXOMA
$85.6M-5.2%
Ligand Pharmaceuticals logo
Ligand PharmaceuticalsLGND
$115.09M+140%
BridgeBio Pharma logo
BridgeBio PharmaBBIO
$882.02M+62.5%
Rigel Pharmaceuticals logo
Rigel PharmaceuticalsRIGL
$24.47M-46.6%
Roivant Sciences logo
Roivant SciencesROIV
$1.42B+1,411%
Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS
$173.38M-34.4%

Other financials

Income statement

See full
Revenue$630.6M+11.0%
Operating income$563.0M+5.4%
Net income$294.7M+23.1%
EPS (diluted)$0.67+21.8%

Balance sheet

See full
Total debt$9.0B+17.8%
Total equity$9.9B+1.6%
Total assets$19.8B+12.5%

Cash flow

See full
Operating cash flow$718.2M+20.5%

Valuation

See full
Market cap$24.85B+72.3%
Enterprise value$33.24B+52.8%
P/E30×+15.9×
P/S10.2×+3.9×

Profitability

See full
Operating margin65.1%-18.9pp
Net margin33.9%-14.4pp

Returns & leverage

See full
Return on equity8.4%-2.7pp
Debt / equity0.9×+0.1×
Current ratio2.7×+1.1×

Where this comes from

Reported directly by Royalty Pharma in its filing.

Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents.

The official record: Royalty Pharma’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Royalty Pharma's cash & equivalents.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Royalty Pharma's cash & equivalents?
Royalty Pharma (RPRX) reported cash & equivalents of $586.4M in Q1 2026.
How has Royalty Pharma's cash & equivalents changed year-over-year?
Royalty Pharma's cash & equivalents decreased by 46.1% year-over-year, from $1.09B to $586.4M.
What is the long-term trend for Royalty Pharma's cash & equivalents?
Over 5 years (2020 to 2025), Royalty Pharma's cash & equivalents has grown at a -9.3% compound annual growth rate (CAGR), from $1.01B to $618.7M.
What does cash & equivalents mean?
Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.